Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice

Japanese Journal of Pharmacology

Volumn 75, Issue 1, 1997, Pages 59-64

  Yotsumoto, Takashi ^a   Naitoh, Takeshi ^a   Shikada, Ken Ichi ^a   Tanaka, Sakuya ^a  

^a NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Angiotensin II receptor antagonist; Angiotensin converting enzyme inhibitor; Diabetic nephropathy; Urinary albumin excretion

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAPTOPRIL; CREATININE; LOSARTAN POTASSIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; KIDNEY HYPERTROPHY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEINURIA; STREPTOZOCIN DIABETES; URINE LEVEL;

EID: 0030730456     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.75.59     Document Type: Article

References (30)

1. Nathan DM: Long-term complications of diabetes mellitus. N Engl J Med 328, 1676-1685 (1993)
2. Viberti GC and Walker JD: Diabetic nephropathy: etiology and prevention. Diabetes Metab Rev 4, 147-162 (1988)
3. Mogensen CE and Christensen CK: Predicting diabetic nephropathy in insulin-dependent patient. N Engl J Med 311, 89-93 (1984)
4. Mogensen CE and Andersen MJF: Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia 11, 221-224 (1975)
5. Foote EF: Prevention and treatment of diabetic nephropathy. Am J Health-Syst Pharm 52, 1781-1792 (1995)
6. Björck S, Mulec H, Johnsen SA, Nordén G and Aurell M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304, 339-343 (1992)
7. Hommel E, Parving HH, Mathiesen E, Edsberg B, Nielsen MD and Giese J: Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 293, 467-470 (1986)
8. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG and Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77, 1925-1930 (1986)
9. Prigent CS, Heudes D, Jouquey S, Auberval D, Belair MF, Michel O, Hamon G, Bariety J and Bruneval P: Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats - protective effects of ACE inhibition. Lab Invest 73, 64-71 (1995)
10. Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Fu LP, Obara K, Saito T and Abe K: Antihypertensive and renal-protective effects of losaltan in streptozotocin diabetic rats. J Hypertens 13, 97-103 (1995)
11. Chiu AT, Duncia JV, McCall DE, Wong PC, Price WA, Thoolen MJMC, Carini DJ, Johnson AL and Timmermans PBMWM: Nonpeptide angiotensin II receptor antagonists. III. Structure-function studies. J Pharmacol Exp Ther 250, 867-874 (1989)
12. Smith RD, Chiu AT, Wong PC, Herblin WWF and Timmermans PBMWM: Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 32, 135-165 (1992)
13. Cogan MG, Liu F, Wong PC and Timmermans PBMWM: Comparison of inhibitory potency by nonpeptide angiotensin II receptor antagonists PD123177 and DuP 753 on proximal nephron and renal transport. J Pharmacol Exp Ther 259, 687-691 (1991)
14. Rasch R and Mogensen CE: Urinary excretion of albumin and total protein in normal and streptozotocin diabetic rats. Acta Endocrinol 95, 376-381 (1980)
15. Daniels BS and Hostetter TH: Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes 38, 981-986 (1989)
16. 1 receptors. Kidney Int 45, 177-184 (1994)
17. Danckwardt L, Shimizu I, Bönner G, Rettig R and Unger T: Converting enzyme inhibition in kinin-deficient Brown Norway rats. Hypertension 16, 429-435 (1990)
18. Hutchison FN and Martin VI: Effects of modulation of renal kallikrein-kinin system in the nephrotic syndrome. Am J Physiol 258, F1237-F1244 (1990)
19. Drury PL: Diabetes and arterial hypertension. Diabetologia 24, 1-9 (1983)
20. Elving LD, Wetzels JFM, de Nobel E, Hoitsma AJ and Berden JHM: Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy. Am J Kidney Dis 20, 559-563 (1992)
21. Yoshida K, Yasujima M, Kohzuki M, Kanazawa M and Abe K: Effects of chronic treatment with calcium channel blockers or angiotensin converting enzyme inhibitors on renal function in streptozotocin-treated hypertensive diabetic rats. Hypertens Res 17, 35-41 (1994)
22. Heeg JE, de Jong PE, van der Hem GK and de Zeeuw D: An giotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. Kidney Int 40, 734-741 (1991)
23. Iso K: Preventive effect of angiotensin-converting enzyme inhibitor on the development of nephropathy in spontaneously hypertensive rats with streptozotocin-induced diabetes. J Jpn Diabetes Soc 38, 375-382 (1995) (Abstr in English)
24. Brenner BM, Hostetter TH and Humes HD: Molecular basis of proteinuria of glomerular origin. N Engl J Med 298, 826-833 (1978)
25. Groggel GC, Stevenson J, Hovingh P, Linker A and Border WA: Changes in heparan sulfate correlate with increased glomerular permeability. Kidney Int 33, 517-523 (1988)
26. Daniels BS, Deen WM, Mayer G, Meyer T and Hostetter TH: Glomerular permeability barrier in the rat. J Clin Invest 92, 929-936 (1993)
27. Miller PL, Scholey JW, Rennke HG and Meyer TW: Glomerular hypertrophy aggravates epithelial cell injury in nephrotic rats. J Clin Invest 85, 1119-1126 (1990)
28. Rosenberg ME and Hostetter TH: Effect of angiotensin II and norepinephrine on early growth response genes in the rat kidney. Kidney Int 43, 601-609 (1993)
29. Wolf G, Haberstroh U and Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140, 95-107 (1992)
30. Mogensen CE: Renal function changes in diabetes. Diabetes 25, 872-879 (1976)